Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 12/2019

Open Access 01-12-2019 | Magnetic Resonance Imaging | Original Article – Cancer Research

Radiomics for diagnosis of dual-phenotype hepatocellular carcinoma using Gd-EOB-DTPA-enhanced MRI and patient prognosis

Authors: Xialing Huang, Liling Long, Jieqin Wei, Yajuan Li, Yuwei Xia, Panli Zuo, Xiangfei Chai

Published in: Journal of Cancer Research and Clinical Oncology | Issue 12/2019

Login to get access

Abstract

Purpose

To describe the clinical characteristics and outcomes of patients with dual-phenotype hepatocellular carcinoma (DPHCC) and investigate the use of radiomics to establish an image-based signature for preoperative differential diagnosis.

Methods

This study included 50 patients with a postoperative pathological diagnosis of DPHCC (observation group) and 50 patients with CK7- and CK19-negative HCC (control group) who attended our hospital between January 2015 and December 2018. All patients underwent Gd-EOB-DTPA-enhanced MRI within 1 month before surgery. Arterial phase (AP), portal venous phase (PVP), delayed phase (DP) and hepatobiliary phase (HBP) images were transferred into a radiomics platform. Volumes of interest covered the whole tumor. The dimensionality of the radiomics features were reduced using LASSO. Four classifiers, including multi-layer perceptron (MLP), support vector machines (SVM), logistic regression (LR) and K-nearest neighbor (KNN) were used to distinguish DPHCC from CK7- and CK19-negative HCC. Kaplan–Meier survival analysis was used to assess 1-year disease-free survival (DFS) and overall survival (OS) in the observation and control groups.

Results

The best preoperative diagnostic power for DPHCC will likely be derived from a combination of different phases and classifiers. The sensitivity, specificity and accuracy of LR in PVP (0.740, 0.780, 0.766), DP (0.893, 0.700, 0.798), HBP (0.800, 0.720, 0.756) and MLP in PVP (0.880, 0.720, 0.798) were better performance. The 1-year DFS and OS of the patients in the observation group were 69% and 78%, respectively. The 1-year DFS and OS of the patients in the control group were 83% and 85%, respectively. Kaplan–Meier survival analysis showed no statistical difference in DFS and OS between groups (P = 0.231 and 0.326), but DFS and OS were numerically lower in patients with DPHCC.

Conclusion

The radiomics features extracted from Gd-EOB-DTPA-enhanced MR images can be used to diagnose preoperative DPHCC. DPHCC is more likely to recur and cause death than HCC, suggesting that active postoperative management of patients with DPHCC is required.
Literature
go back to reference Bosman FT, World HO, International AFRO (2010) WHO classification of tumours of the digestive system. International Agency for Research on Cancer, Lyon Bosman FT, World HO, International AFRO (2010) WHO classification of tumours of the digestive system. International Agency for Research on Cancer, Lyon
go back to reference Chen S, Feng S, Wei J et al (2019) Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging. Eur Radiol 29:4177–4187CrossRef Chen S, Feng S, Wei J et al (2019) Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging. Eur Radiol 29:4177–4187CrossRef
go back to reference Chinese Society of Liver Cancer, Chinese Anti-Cancer Association, Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Pathology, Chinese Anti-Cancer Association et al (2015) Evidence based practice guidelines for the standardized pathological diagnosis of primary liver cancer in China (2015 update). Chin J Clin Hepatol 31:833–839 Chinese Society of Liver Cancer, Chinese Anti-Cancer Association, Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Pathology, Chinese Anti-Cancer Association et al (2015) Evidence based practice guidelines for the standardized pathological diagnosis of primary liver cancer in China (2015 update). Chin J Clin Hepatol 31:833–839
go back to reference Cong WM, Bu H, Chen J et al (2016) Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol 22:9279–9287CrossRef Cong WM, Bu H, Chen J et al (2016) Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol 22:9279–9287CrossRef
go back to reference Esterson YB, Flusberg M, Oh S et al (2015) Improved parenchymal liver enhancement with extended delay on Gd-EOB-DTPA-enhanced MRI in patients with parenchymal liver disease: associated clinical and imaging factors. Clin Radiol 70:723–729CrossRef Esterson YB, Flusberg M, Oh S et al (2015) Improved parenchymal liver enhancement with extended delay on Gd-EOB-DTPA-enhanced MRI in patients with parenchymal liver disease: associated clinical and imaging factors. Clin Radiol 70:723–729CrossRef
go back to reference Gao F, Yan B, Zeng L et al (2019) Quantitative analysis of hepatocellular carcinomas pathological grading in non-contrast magnetic resonance images. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 36:581–589PubMed Gao F, Yan B, Zeng L et al (2019) Quantitative analysis of hepatocellular carcinomas pathological grading in non-contrast magnetic resonance images. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 36:581–589PubMed
go back to reference Guo D, Gu D, Wang H et al (2019) Radiomics analysis enables recurrence prediction for hepatocellular carcinoma after liver transplantation. Eur J Radiol 117:33–40CrossRef Guo D, Gu D, Wang H et al (2019) Radiomics analysis enables recurrence prediction for hepatocellular carcinoma after liver transplantation. Eur J Radiol 117:33–40CrossRef
go back to reference Huang X, Cheng Z, Huang Y et al (2018) CT-based radiomics signature to discriminate high-grade from low-grade colorectal adenocarcinoma. Acad Radiol 25:1285–1297CrossRef Huang X, Cheng Z, Huang Y et al (2018) CT-based radiomics signature to discriminate high-grade from low-grade colorectal adenocarcinoma. Acad Radiol 25:1285–1297CrossRef
go back to reference Kim S, Shin J, Kim DY et al (2019) Radiomics on gadoxetic acid-enhanced magnetic resonance imaging for prediction of postoperative early and late recurrence of single hepatocellular carcinoma. Clin Cancer Res 25:3847–3855CrossRef Kim S, Shin J, Kim DY et al (2019) Radiomics on gadoxetic acid-enhanced magnetic resonance imaging for prediction of postoperative early and late recurrence of single hepatocellular carcinoma. Clin Cancer Res 25:3847–3855CrossRef
go back to reference Lambin P, Rios-Velazquez E, Leijenaar R et al (2012) Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 48:441–446CrossRef Lambin P, Rios-Velazquez E, Leijenaar R et al (2012) Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 48:441–446CrossRef
go back to reference Lee JI, Lee JW, Kim JM et al (2012) Prognosis of hepatocellular carcinoma expressing cytokeratin 19: comparison with other liver cancers. World J Gastroenterol 18:4751–4757CrossRef Lee JI, Lee JW, Kim JM et al (2012) Prognosis of hepatocellular carcinoma expressing cytokeratin 19: comparison with other liver cancers. World J Gastroenterol 18:4751–4757CrossRef
go back to reference Lee CW, Kuo WL, Yu MC et al (2013) The expression of cytokeratin 19 in lymph nodes was a poor prognostic factor for hepatocellular carcinoma after hepatic resection. World J Surg Oncol 11:136CrossRef Lee CW, Kuo WL, Yu MC et al (2013) The expression of cytokeratin 19 in lymph nodes was a poor prognostic factor for hepatocellular carcinoma after hepatic resection. World J Surg Oncol 11:136CrossRef
go back to reference Lee G, Bak SH, Lee HY et al (2019) Measurement variability in treatment response determination for non-small cell lung cancer: improvements using radiomics. J Thorac Imaging 34:103–115CrossRef Lee G, Bak SH, Lee HY et al (2019) Measurement variability in treatment response determination for non-small cell lung cancer: improvements using radiomics. J Thorac Imaging 34:103–115CrossRef
go back to reference Li L, Wang H (2015) Heterogeneity of liver cancer and personalized therapy. Cancer Lett 379:191–197CrossRef Li L, Wang H (2015) Heterogeneity of liver cancer and personalized therapy. Cancer Lett 379:191–197CrossRef
go back to reference Liu LZ, Yang LX, Zheng BH et al (2018) CK7/CK19 index: a potential prognostic factor for postoperative intrahepatic cholangiocarcinoma patients. J Surg Oncol 117:1531–1539CrossRef Liu LZ, Yang LX, Zheng BH et al (2018) CK7/CK19 index: a potential prognostic factor for postoperative intrahepatic cholangiocarcinoma patients. J Surg Oncol 117:1531–1539CrossRef
go back to reference Oyama A, Hiraoka Y, Obayashi I et al (2019) Hepatic tumor classification using texture and topology analysis of non-contrast-enhanced three-dimensional T1-weighted MR images with a radiomics approach. Sci Rep 9:8764CrossRef Oyama A, Hiraoka Y, Obayashi I et al (2019) Hepatic tumor classification using texture and topology analysis of non-contrast-enhanced three-dimensional T1-weighted MR images with a radiomics approach. Sci Rep 9:8764CrossRef
go back to reference Sequist LV, Waltman BA, Dias-Santagata D et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:26r–75rCrossRef Sequist LV, Waltman BA, Dias-Santagata D et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:26r–75rCrossRef
go back to reference Tanimoto A, Higuchi N, Ueno A (2012) Reduction of ringing artifacts in the arterial phase of gadoxetic acid-enhanced dynamic MR imaging. Magn Reson Med Sci 11:91–97CrossRef Tanimoto A, Higuchi N, Ueno A (2012) Reduction of ringing artifacts in the arterial phase of gadoxetic acid-enhanced dynamic MR imaging. Magn Reson Med Sci 11:91–97CrossRef
go back to reference Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108CrossRef Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108CrossRef
go back to reference Zhao W, Liu W, Liu H et al (2018) Preoperative prediction of microvascular invasion of hepatocellular carcinoma with IVIM diffusion-weighted MR imaging and Gd-EOB-DTPA-enhanced MR imaging. PLoS One 13:e197488 Zhao W, Liu W, Liu H et al (2018) Preoperative prediction of microvascular invasion of hepatocellular carcinoma with IVIM diffusion-weighted MR imaging and Gd-EOB-DTPA-enhanced MR imaging. PLoS One 13:e197488
Metadata
Title
Radiomics for diagnosis of dual-phenotype hepatocellular carcinoma using Gd-EOB-DTPA-enhanced MRI and patient prognosis
Authors
Xialing Huang
Liling Long
Jieqin Wei
Yajuan Li
Yuwei Xia
Panli Zuo
Xiangfei Chai
Publication date
01-12-2019
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 12/2019
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-019-03062-3

Other articles of this Issue 12/2019

Journal of Cancer Research and Clinical Oncology 12/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.